MEF2D Aggravates Hepatic Ischaemia-Reperfusion Injury by Transcriptionally Regulating CXCL1 Through Interacting With NAT10.

Background And Aims: Hepatic ischaemia-reperfusion injury (IRI), a common complication after hepatectomy and liver transplantation (LT), is a local sterile inflammatory response driven by innate immunity. Myocyte enhancer factor-2D (MEF2D) plays an important role in immune inflammatory response by transcriptionally activating or inhibiting gene expression, which is tightly associated with the pathogenic progression of hepatic disorders. However, the role of MEF2D in hepatic IRI is still unclear.

Fibronectin-assisted reactive oxygen species-responsive mesoporous silica-loaded epigallocatechin-3-gallate for treating diabetic nephropathy by enhancing autophagy and regulating M1-type macrophage polarization.

Diabetic nephropathy (DN) is the main factor contributing to end-stage renal disease and is often associated with oxidative stress caused by hyperglycemia. Targeting reactive oxygen species (ROS) is a promising strategy for treating DN, and multifunctional drug delivery systems can assist in DN therapy. In this study, we developed an oxide-responsive nanoparticle (NP) system based on fibronectin (FN)-coated, methoxy polyethylene glycol thioketal (TK)-modified mesoporous silica (MSN) encapsulated with epigallocatechin-3-gallate (EGCG) (FN@EGCG-MSN-TK).